Ensign Peak Advisors Inc Has $16.67 Million Stock Holdings in Insulet Co. (NASDAQ:PODD)

Ensign Peak Advisors Inc decreased its position in Insulet Co. (NASDAQ:PODD) by 9.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 63,865 shares of the medical instruments supplier’s stock after selling 6,500 shares during the period. Ensign Peak Advisors Inc’s holdings in Insulet were worth $16,673,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. bought a new stake in Insulet during the 4th quarter worth about $42,000. SRS Capital Advisors Inc. boosted its stake in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 56 shares during the last quarter. Friedenthal Financial bought a new position in shares of Insulet in the 4th quarter valued at about $57,000. Finally, Assetmark Inc. grew its holdings in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 246 shares in the last quarter.

Insulet Trading Up 20.8%

Shares of PODD stock opened at $310.42 on Monday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $312.80. The company has a market capitalization of $21.84 billion, a PE ratio of 53.61, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. The firm has a 50 day moving average price of $257.45 and a two-hundred day moving average price of $263.88. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.73 earnings per share. As a group, analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

PODD has been the topic of several analyst reports. Piper Sandler upped their target price on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Wells Fargo & Company set a $322.00 target price on shares of Insulet in a report on Monday, April 28th. Canaccord Genuity Group upped their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Royal Bank of Canada started coverage on shares of Insulet in a research report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective for the company. Finally, Wolfe Research cut shares of Insulet from an “outperform” rating to a “peer perform” rating in a report on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $303.81.

Insiders Place Their Bets

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.